Molecular Landscape in Alveolar Soft Part Sarcoma: Implications for Molecular Targeted Therapy

Biomed Pharmacother. 2018 Jul:103:889-896. doi: 10.1016/j.biopha.2018.04.117. Epub 2018 Apr 24.

Abstract

Alveolar soft part sarcoma (ASPS) is a highly aggressive rare soft tissue sarcoma (STS) with poor prognosis especially in the metastatic form. ASPS is resistant to standard chemotherapy. Although, early diagnosis and surgical resection of operable tumor could lead to improved patient survival but novel treatment options are needed for advanced (metastatic) ASPS. This malignancy exhibits highly angiogenic behavior which reflects hyper-activation and over expression of angiogenic factors. Understanding the molecular events in this type of sarcoma is important in finding novel molecular based targeted therapies. We aim to review molecular aspects of ASPS growth and treatment.

Keywords: Alveolar soft part sarcoma; Drug resistance; Molecular targeted therapy; Tyrosine kinase inhibitor.

Publication types

  • Review

MeSH terms

  • Angiogenesis Inhibitors / therapeutic use*
  • Humans
  • Molecular Targeted Therapy / methods*
  • Neoplasm Metastasis
  • Neovascularization, Pathologic / drug therapy*
  • Neovascularization, Pathologic / metabolism
  • Sarcoma, Alveolar Soft Part* / drug therapy
  • Sarcoma, Alveolar Soft Part* / metabolism
  • Sarcoma, Alveolar Soft Part* / pathology
  • Treatment Outcome

Substances

  • Angiogenesis Inhibitors